by 
Cell-based assays are complex in vitro techniques that measure the potency of test substances based on their effect on living cells. These assays are commonly used in pharmaceutical research and drug discovery to study cell signaling pathways and identify molecular mechanisms of drug action. Additionally, cell-based assays are widely utilized to detect cytotoxicity, cell proliferation, and cell health. Recently, cell-based assays are gaining significant traction in high-throughput screening that enables evaluation of large chemical libraries to identify lead compounds for drug development. The rising adoption of high-throughput screening techniques by biopharmaceutical companies is expected to drive the demand for cell-based assays over the forecast period.
The global cell-based assay market is estimated to be valued at US$ 1389.5 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing adoption of high-throughput screening: High-throughput screening allows researchers to analyze thousands of chemical and biological test agents rapidly. Cell-based assays find wide applicability in high-throughput screening as they are reliable, reproducible, and sensitive to detect potency and efficacy of lead compounds at an early stage of drug discovery. The rising adoption of high-throughput screening by pharmaceutical and biotechnology companies to hasten the drug discovery process is expected to drive the demand for cell-based assays over the forecast period.
Rising incidence of chronic diseases: The increasing prevalence of chronic diseases such as cancer and cardiovascular diseases is prompting biopharmaceutical companies to focus on the development of new drugs. Cell-based assays serve as an effective tool for target identification, lead optimization, and toxicity screening in early drug discovery stages. Therefore, the growing efforts towards developing novel treatment options for chronic diseases are anticipated to boost the cell-based assay market during the forecast period.
Segment Analysis
The cell-based assay market comprises the consumables and reagents, instruments, and services segments. The consumables and reagents segment is further divided into cell lines, antibodies and probes, toxins, growth factors, cytokines, chemokines, and others. The consumables and reagents segment dominated the market in 2023 owing to high repeat purchasing required on these products compared to one-time purchase of instruments. Within the consumables segment, the antibodies and probes segment accounted for the largest share due to widespread usage of antibodies in various assay applications.
PEST Analysis
Political: The cell based assay market is regulated by government bodies and faces stringent regulations regarding use of live cell lines and testing of novel reagents and kits. This impacts approval timelines for new market entrants.
Economic: Rising investments in life sciences research and drug discovery has created demand for cost-effective and high throughput cell based assays. The market is fueled by outsourcing of R&D activities by pharmaceutical companies to contract research organizations.
Social: Growing awareness regarding cell based assays amongst research organizations and availability of public domain knowledge has increased adoption of these techniques for toxicity screening, compound profiling and target validation.
Technological: Advanced technologies such as high content screening, label-free detection and microfluidic 3D cell cultures have augmented capabilities of cell based assays. This is supporting development of more predictive and physiologically relevant models for drug development.
Key Takeaways
The global cell-based assay market is expected to witness high growth over the forecast period supported by continuous technological advancements, increased R&D spending on drug discovery, and growing prevalence of chronic diseases.
The North American region currently dominates the market owing to presence of leading global players, availability of funding for life sciences research, and high adoption of advanced technologies. The Asia Pacific region is expected to grow at the fastest pace during the forecast period with increasing government funding and investments by international players to establish manufacturing and R&D centers in countries such as China and India.
Key players operating in the cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., and PerkinElmer, Inc. The market is competitive in nature with these players focusing on new product launches, expansions, and collaborations to enhance their product portfolio and market share. For instance, in 2022 Danaher Corporation acquired Massachusetts-based rights to Olink AB’s high multiplex proteomics platform which strengthened its proteomics solutions for biopharma and life science research.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
